The lower basal metabolic rate is associated with increased risk of osteosarcopenia in postmenopausal women

Zhila Maghbooli1*, Sadegh Mozaffari2, Yasaman Dehghani3, Pedram Rezaei Amirkiasar2, Ali Asghar Malekhosseini3, Mohamad Taher Rezanejad4 and Michael F. Holick5

Abstract

Background: The goal of this study is to clarify clinical, functional, and biochemical features of postmenopausal women who are at risk of developing osteosarcopenia.

Methods: This is a cross-sectional study undertaken to investigate the co-accordance of osteoporosis and sarcopenia and common risk factors on 305 postmenopausal Iranian women. Sarcopenia and osteoporosis were defined based on the European Working Group on sarcopenia in Older People guidelines and WHO criteria, respectively. Confounding factors including age, menopausal age, obesity, sun exposure, physical activity, macronutrient composition, and calcium and vitamin D supplementations were considered for all participants. A multivariate model was used to consider the common risk factors of both disorders; osteoporosis and sarcopenia.

Results: The mean age was 57.9 years ± 6.0 SD (range: 48–78 years) and 37.4% of patients were 60 years or older. Among all participants, 35.7% were obese (BMI ≥ 30 kg/m²). Approximately 45% of all the study population had insufficient physical activity and at least half of participants had insufficient intake of protein. There was a significant correlation between bone density and muscle mass and basal metabolic rate (BMR) (p < 0.01). In multivariate-multivariable regression model, after Bonferroni correction for obesity, lower BMR was the only one associated with both lower muscle mass and bone density in lumbar and hip sites (p < 0.007).

Conclusions: Our data suggest that low BMR might be an early predictor for concordance of osteoporosis and sarcopenia in postmenopausal women.

Keywords: Basal metabolic rate, Obesity, Osteoporosis, Sarcopenia, Osteosarcopenia

Background

Aging is raising principal health concerns as it predisposes to the risk of chronic disease among elderly people. Of these, osteoporosis and sarcopenia—two major musculoskeletal diseases—have been come into focus as these conditions are highly associated with increased morbidity and mortality worldwide, which poses a significant global health burden on the healthcare system.

Sarcopenia is described by attenuated muscle strength, loss of muscle mass, and decreased physical performance [1]. In this condition, a myriad of progressive age-related skeletal muscle loss alongside the disturbing muscular function (strength or physical performance) affects the routine daily activities, and escalates the risk of falls in particular [2]. In a population of postmenopausal women, the prevalence of sarcopenia ranges from 10 to 40% [3].
On the other hand, osteoporosis is a systemic bone disease that reduces bone microarchitecture and impedes bone strength which in turn leads to an increased risk of developing fractures even after subtle falls [2]. Osteoporosis affects roughly 30% of postmenopausal women who are above 50 years old [3].

However, a subset of older persons is affected by osteosarcopenia as a clinical condition in which the coexistence of osteoporosis and sarcopenia occurs. In this condition, the musculoskeletal system represents a trend towards low bone and muscle mass, while increased ectopic fat. This coexistence which is also stated as a “hazardous duet”, discriminates individuals at higher risk of falls, fractures, hospitalization, frailty, and mortality [4]. These negative consequences require proper detection and clinical care [5]. When the muscle strength and muscle mass start to evanescence, gradual loss of the ability to have an independent life appears and following affecting an individual turns out to be a troublesome social dilemma. Multi-morbidity is a prevalent incident that is observed in older people preponderantly. As the reason, disorders like heart failure or chronic obstructive pulmonary disease, expedite the loss of muscle mass and strength, thereby collaborating [6]. All of the points mentioned above, convey the concept of poor life quality burdened on the elderly patients [1].

A plethora of studies have demonstrated that a constellation of biochemical and genetic factors interacts with each other that increase the risk of osteoporosis and sarcopenia in elderly people. Specifically, bone and muscle could make an interaction by different anatomic, chemical, and metabolic aspects [2]. Previous studies have endorsed the presence of a communicative bridge over bone and muscle tissue which implies various paracrine and endocrine mechanisms to affect myokines and osteokines levels [7, 8]. These studies have also indicated a strong correlation between lean body mass (LBM) and bone mineral density (BMD) in women after menopause [7, 8].

Also, sarcopenia and increased fat mass can modify the energy metabolic rate and consequently basal metabolic rate (BMR) in postmenopausal women [9]. Several data point that a decrease in skeletal muscle reflected by the loss of LBM in patients with sarcopenia and an increase in adipose tissue cause a lower BMR [10, 11].

Recently, a tremendous effort has been made to identify the multiple factors that contribute to osteosarcopenia development in people with osteoporosis and osteopenia. However, uncertainty remains which risk factors could promote the coexistence of osteoporosis and sarcopenia that known osteosarcopenia in postmenopausal women. Here, we aimed to clarify clinical, functional, and biochemical features of postmenopausal women who are at risk of developing osteosarcopenia.

**Methods**

**Study design and population**

A cross-sectional study was undertaken to investigate the co-accordance of osteoporosis and sarcopenia and common risk factors on 305 postmenopausal Iranian women from the first of January to April 2016.

Participants were postmenopausal women who referred voluntarily undergone a routine health examination at the endocrinology clinic of Shariati hospital, Tehran, Iran. Written informed consent was obtained from all study participants in accordance with procedures approved by the Ethical Committee of Tehran University of Medical Sciences. Postmenopausal women with serious and/or chronic illnesses, especially those with diabetes mellitus, heart, liver, and kidney disorders and use of steroidal drugs (prednisolone, dexamethasone, and betamethasone), use of hormone therapy within the last 6 months, or use of antosteoporotic drugs (raloxifene and bisphosphonates) in the last 2 years were not eligible to participate in the study. Only five women had a history of smoking that were excluded of data analyses. None of participants had a history of alcohol consumption.

**Data collection**

Demographic and clinical information including age, menopausal age, and current use of medications and vitamin supplementations within the last 6 months were obtained by a questionnaire. Anthropometric measurements of the participants were taken using standard anthropometric techniques. Body mass index (BMI) was calculated as body weight (in kilograms) divided by height (in meters) squared. Obesity was defined as having BMI equal to/or more than 30 kg/m² [12].

**Bone status measurements**

Dual X-ray absorptiometry with a Lunar DPXMD densitometer (Lunar 7164, GE, and Madison, WI, USA) was used to assess the BMD in two bone sites: Total hip, and spinal lumbar vertebras (L2–L4). Precision error in BMD measurements was 1–1.5% in the lumbar and 2–2.5% in the hip regions. Each person was categorized based on the WHO osteoporosis criteria: Osteoporosis (T score ≤ −2.5), osteopenia (−2.5 < T score < −1) and normal (T score ≥ −1).

**Sarcopenia definition**

To identify sarcopenia, we used the EWGSOP (European Working Group on Sarcopenia in Older People) criteria (2018) [2]. Probable sarcopenia is identified by
low muscle strength. The diagnosis of sarcopenia is confirmed by low muscle strength plus low muscle mass.

Participants who only have low muscle mass were classified as presarcopenia; those who have low muscle mass plus low muscle strength, or low physical performance were as sarcopenia.

**Muscle strength**

Muscle strength was assessed by handgrip strength, which was measured with a dynamometer (Jamar dynamometer). Three trials for each hand were performed and the average measurements of both hands were used in the analysis. Using the cut-off points suggested for different sex–age groups less than 19.7 kg for women.

**Muscle mass**

Muscle mass was estimated by Bioelectrical impedance analysis (BIA) resistance (Tanita BC-418 manufactured by Tanita Corporation, Tokyo, Japan). The appendicular muscle mass index (ASMI) was calculated by the following equation: skeletal muscle mass (kg) divided by the square of height (m²). To assess reproducibility, whole-body DEXA was used for 20% of participants for muscle mass assessment with Cronbach’s Alpha equal 0.92. Percentage Fat Mass (PFM) (the ratio of fat mass to body weight) and basal metabolic rate (BMR) (Kcal/24 h) were estimated by the same BIA equipment. Low muscle mass was defined as an ASMI ≤ 5.7 kg/m².

**Physical performance**

Usual walking speed on a 4-m course was evaluated by measuring subjects’ gait speed (meter/second). The cut-off ≤ 0.8 m/s was classified as of low physical performance. Nobody had a history of disability of walking.

**Biochemical measurements**

Blood samples were taken after at least 10 h of overnight fasting. The separate sera were kept at − 80 °C until analysis. 25(OH)D was measured using an electrochemiluminescence assay (ELECSYS® Vitamin D assay, Roche, Germany). A cut-off value of 30 ng/mL was used for optimal vitamin D status; vitamin D deficiency/insufficiency was defined as 25(OH)D less than 30 ng/mL [12, 13].

**Dietary assessments**

Dietary intakes were assessed by a validated semi-quantitative 146-item food frequency questionnaire (FFQ) [14]. Participants were asked to report their usual frequency of consumption for each FFQ item and also the amounts of intakes based on the serving sizes which are noted in the FFQ over the past year. Dietary intakes of each food were then converted to grams per day and the nutrient contents of food items (Macronutrients) were calculated according to the USDA food composition databases. Macro nutrition percentages were calculated based on total energy.

**Sun exposure**

For sun exposure, a questionnaire was completed including 4 questions; time per day, day time, an average time of sun exposure, and using sunscreen during the last three months. Sun exposure was classified based on at least 10 min per day at daytime (between 10 am to 3 pm).

**Physical activity**

The short format of the International Physical Activity Questionnaire (IPAQ) was used to assess physical activity [15]. Following IPAQ’s guidelines, frequency and duration of physical activity were converted to Metabolic Equivalent of Tasks (MET). Physical activity was classified into three levels: inactive, moderate activity, and health- enhancing physical activity (HEPA).

**Statistical analysis**

Data were analyzed by SPSS statistical software SPSS® 20 (IBM Corporation, Armonk, NY, USA). ANOVA and post hoc tests and Chi-square test were applied to consider the difference between confounding factors in women with osteoporosis, osteopenia, and normal bone density. A Pearson’s correlation was used to determine the correlation between bone density and muscle mass and risk factors including age, menopausal age, BMI, and macronutrients.

Univariate linear regression model was used to consider the correlation between confounding factors and bone and muscle status. A multivariate-multiple linear regression model was used to consider the common risk factors of both disorders. The dependent factors were the bone density in lumbar and/or hip sites (T-score), and the appendicular muscle mass index (ASMI). The covariates were age, menopausal age, macronutrients, and BMR. The fix factors were sun exposure, physical activity, taking calcium and vitamin D supplementations and obesity. If p value was less than 0.2 (p value < 0.2), the cofactor was adjusted in the multivariate model.

Numerical variables were expressed as the mean ± standard error (SE), and categorical variables were presented as percentages. Two-tailed p values less than 0.05 were considered significant.

**Results**

A total of 305 postmenopausal Iranian women were enrolled in this study. The mean age was 57.9 years ± 6.0 SD (range: 48–78 years) and 37.4% of patients were...
60 years or older. Bone status and muscle mass were considered for all women.

The baseline characteristics of all participants are presented in Table 1. Confounding factors including obesity, sun exposure, physical activity, macronutrient composition and calcium, and vitamin D supplementations were considered for all participants (Table 1). Among all participants, 35.7% were obese (BMI ≥ 30 kg/m²).

Approximately half of all study population had insufficient physical activity (44.7%). Macronutrients including carbohydrates, fat, and protein were calculated based on total energy. Among all participants, the range of protein intake was 9–24% and 58.8% of women had insufficient intake of protein; less or equal to 15%.

Circulating serum concentrations of 25(OH) D were measured in 195 women with mean 37.7 ng/ml ± 18.8 SD.

Table 1: Demographic characteristics and biochemical analyses and skeletal-muscle status of the study population

| Demographic characteristic                  | N  | Total      | Min  | Max  |
|---------------------------------------------|----|------------|------|------|
| Age (year)†                                  | 305| 58 ± 6     | 46.0 | 78.0 |
| Menarche age (year)†                         | 305| 13 ± 1     | 9    | 18   |
| Menopause age (year)†                        | 305| 48 ± 5     | 34.0 | 62.0 |
| Gravity†                                     | 305| 4 ± 2      | 0    | 12   |
| Parity‡                                      | 305| 3 ± 2      | 0    | 10   |
| Lactation (month)‡                           | 305| 36 (45)    | 0    | 192  |
| BMI (kg/m²)‡                                 | 305| 28.6 ± 4.6 | 17.5 | 41.9 |
| Physical activity                           | 292|            |      |      |
| Insufficiently activity                     |    | 44.9% (131)|      |      |
| Minimally activity                          |    | 36.3% (106)|      |      |
| HEPA activity                               |    | 18.8% (55) |      |      |
| Vitamin D supplementation                   | 305| 25.5% (78) |      |      |
| Calcium supplementation                     | 305| 45.2% (138)|      |      |
| Sun exposure (equal or more than 10 min/10 am to 3 pm) | 301| 40.9% (123)|      |      |
| Sun screen (using usually or always)        | 301| 41.5% (125)|      |      |
| Bone status                                 | 305|            |      |      |
| Osteoporosis                                |    | 21.0% (64) |      |      |
| Osteopenia                                  |    | 51.8% (158)|      |      |
| Normal                                      |    | 27.2% (83) |      |      |
| Muscle status                               |    |            |      |      |
| Appendicular muscle mass index (ASM/hight²)‡| 305| 7.1 ± 0.9  | 4.43 | 9.37 |
| Low (≤ 5.76)                                |    | 9.2% (28)  |      |      |
| Moderate (5.76–6.76)                        |    | 23.9% (73) |      |      |
| Normal (≥ 6.76)                             |    | 66.9% (204)|      |      |
| Handgrip strength (Muscle strength) ≤ 19.7 kg| 271| 43.9% (108)|      |      |
| Gait speed (Physical performance) ≤ 0.8 m/s  | 216| 19.9% (43) |      |      |
| Macro-nutrients                             |    |            |      |      |
| Total protein (Percentage of energy)‡        | 305| 15 ± 2     | 9    | 24   |
| Total carbohydrate (Percentage of energy)‡   | 305| 61 ± 5     | 39   | 74   |
| Total fat (Percentage of energy)‡            | 305| 28 ± 5     | 18   | 67   |
| Total energy intake (kcal)‡                  | 305| 2173 ± 425 | 1171 | 3618 |
| Body composition                            |    |            |      |      |
| Fat (%)‡                                    | 305| 37 ± 6     | 14   | 60   |
| BMR (kcal)‡                                  | 305| 1320 ± 132 | 948  | 1744 |
| FFM (kg)‡                                   | 305| 42 ± 7     | 10   | 70   |

Numerical variables were expressed as the mean ± SD and categorical variables were presented as percentages. BMI = body mass index, BMR = basal metabolism rate, FFM = free fat mass, HEPA = health-enhancing physical activity.

N = available data for each variable, Min = minimum, Max = maximum, Ln = natural logarithm.

† Mean ± SD
‡ Median (IQR)
(range: 3.2–79.9 ng/ml). A cutoff point less than 30 ng/mL of 25(OH)D was used for the definition of vitamin D deficiency/insufficiency. In total, 36.4% of the patients had a 25(OH)D level of less than 30 ng/mL.

**Bone status**

Among all participants, 21.0% (83) had osteoporosis with a T-score of less than −2.5 in at least one region (total hip, or lumbar); 13.11% (40) with a T-score of equal or less than −3. Based on osteoporosis classification, the baseline characteristics of participants are summarized in Additional file 1: Table S1.

**Muscle status**

Based on EWGSOP criteria (2018), about 40% of women were diagnosed as having probable sarcopenia (weak muscle strength), and 15.1% suffered from both low muscle mass and weak muscle strength.

**Co-acordance risk of osteoporosis and sarcopenia (osteosarcopenia) in postmenopausal women**

In Pearson’s correlation analysis, there was a significant positive correlation between bone density (T-score hip, and T-score L2–L4) and ASMI (p < 0.01) (Table 2). There was a significant correlation between bone density and muscle mass and age, BMR, and BMI (p < 0.01). There were no significant correlations between bone density and muscle mass with menopausal age in our study population. There was no significant correlation between bone density and ASMI with 25(OH)D (Table 2).

To address the risk factors associated with osteosarcopenia in our population study, a univariate model was used to assess the association between risk factors and bone density (Hip T-score and Lumbar T-score) and muscle mass (ASMI), separately. In the univariate model, after adjusting confounding factors [age, obesity, physical activity, and percentage of protein consumption (p value < 0.2)], BMR had independently a significant association with muscle mass (p = 0.0001).

In multivariate model, after Bonferroni correction for obesity, only lower BMR was associated with both lower muscle mass and bone density in lumbar (p < 0.006) and/or hip sites (p = 0.0001) with adjusted R-square = 0.56.

**Discussion**

There is ample evidence that sarcopenia and osteoporosis share common risk factors and also share the same biological pathways [4]. In our current study, we showed that lower BMR was independently associated with both lower muscle mass and bone density in lumbar and hip sites. In line with our results, Soysal et al. had reported a linkage between a lower BMR and the upcoming emergence of sarcopenia and frailty in elderly men. The authors mentioned the ratio of BMR to body surface area, which used to contradict the effect of height and weight on BMR, could be expressed as an objective feasible screening method for sarcopenia [16]. In another study, it was suggested that BMR might be a predictor for osteoporosis as they found that BMR and body fat significantly predicted BMD of the femoral neck and vertebral BMD among women over 50 years of age [17].

Once humans take steps into senescence, conditions such as reduced total energy expenditure and energy availability start to appear [16, 18]. More importantly, energy metabolism and body composition are highly interrelated; a higher basal metabolic rate reflects the metabolically active tissue [18, 19], and the skeletal muscle tissue is stated to consume the highest amount of energy needed to meet the entire human body requirements [16].

Although it was beyond our scope to determine how decreased BMR can be considered as a possible risk factor associated with osteosarcopenia, several possibilities can be considered. By modeling, we tried to minimize the effect of main confounding factors including age, menopausal age, obesity, physical activity, macronutrient composition, and vitamin D intake, but they may modify the association between lower BMR

| Table 2 The relationship between bone and muscle mass status and osteosarcopenia risk factors |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|
|                                | ASMI   | Age     | Menopausal age | BMR      | BMI           |
| Hip T-score                    | 0.2**  | −0.2**  | 0.01           | 0.3**    | 0.2**         |
| Lumbar L2–L4 T-score           | 0.1**  | −0.2**  | 0.009          | 0.2**    | 0.1*          |
| ASMI                            | 1      | 0.009   | −0.07          | 0.7**    | 0.8**         |

ASM1 appendicular muscle index, BMR basal metabolism rate, BMI body mass index, FFM free fat mass

Boldface indicates statistical significance (p value < 0.05)

*p Value < 0.01

**p Value < 0.0001
and risk of osteosarcopenia through different cellular mechanisms. Evidence points to a decrease in BMR with advancing age. BMR is the energy expended by a person at rest and accounts for approximately 60–75% of daily energy expenditure in individuals with a sedentary lifestyle. Reduced energy consumption is not only emerged by declined BMR but also observed alongside the decreased intensity and duration of physical activities. Additionally, reduced fat oxidation might give rise to the diminution of postprandial energy expenditure [16, 19]. Moreover, BMR tends to increase with inflammatory conditions or age-related chronic diseases [16, 20].

Fat-free mass (FFM) is the most significant factor which determines BMR, and age is also known as one of the most important regulators of energy metabolism. In fact, skeletal muscle loss in sarcopenia results in BMR reduction by roughly 30% between the ages of 20 and 70 years [16]. Noticeably, in our study, BMR also had a significant positive correlation with FFM and a negative correlation with age.

Although the protein synthesis in the skeletal muscle is influenced by its degradation, bone formation is modulated by its resorption. An imbalanced adjustment of the mentioned mechanisms will give rise to low BMD and/or sarcopenia. Both conditions tend to be multifactorial and also have various pathophysiological pathways in common [2]. Among our population study, the range of protein intake in postmenopausal women was 9–24% and over half of participants had less or equal 15% protein intake.

In our study obesity was a common risk factor for both osteoporosis and sarcopenia. The emerging evidence shows that fat tissue influence the skeleton system. There is a report that fat tissue exerts its protective effects through applying its buffering characteristics which protect the bones from fragility. Several studies indicated that a higher BMI represents a protective factor against the presence of osteosarcopenia [1, 21–27]. While other investigations have clearly shown that high BMI and low body mass have deleterious effects on the disease progression leading to the increased mechanical pressure on bones and the diminution of muscular support as well [28]. Fatty infiltration of bone and muscle is mostly related to the negative effects caused by the secretion of inflammatory cytokines from bone marrow and body fat in an especial process called lipotoxicity [29]. Several endocrine factors such as insulin-like growth factor-1, osteoglycin, irisin, osteonectin, fibroblast growth factor-2, IL-6, IL-15, and myostatin are released from muscle and affect bones subsequently [30].

Concomitant to the onset of the aging process, diminution of physical activity overshadows the entire elderly lifestyle resulting in the substantial increase in the time spent sedentarily [8, 31], thereby the conditions like mechanical loading loss and bone and muscle wreckage are likely to appear subsequently [8, 32]. In our study population, around 80% of women had insufficiency/minimum activity. Because sun exposure declines by around 25% between the ages of 40 and 70 years [8, 33], this results in decreased vitamin D production and lower circulating levels of 25(OH)D, putting postmenopausal women at risk of muscle weakness [8, 34] as well as bone loss. Additionally, deficient levels of vitamin D underlie the augmented risk of falls through its multiple effects on muscle and bone [8, 35]. In our study, although 36.4% of the women had vitamin D deficiency/insufficiency, there was not any significant correlation between bone and muscle mass status with circulating levels of vitamin D. However, measuring vitamin D levels in the blood at a single point in time may not reflect a person’s true vitamin D status.

Some limitations in our study are worth noting. Firstly, postmenopausal women are at risk of osteoporosis, while people older than 65 are more at risk of sarcopenia. However, to identify individuals who are likely to be at risk of development of both osteoporosis and sarcopenia, we considered postmenopausal women. Occurrence of BMD loss accompanied by gradually declining muscle mass, strength, and function concomitantly has been introduced to identify risk factors sarcopenia in women with osteopenia/osteoporosis. Secondly, it was documented that smoking increases the risk of developing sarcopenia. In this consent, a recent cohort study considered the role of smoking on the risk of sarcopenia [36]. They mentioned that “smokers have a 2.36-fold higher risk of developing sarcopenia”. In our data, only 5 women had a history of smoking that were excluded of the analysis. Lastly, the design of our study is cross-sectional. So, we cannot explain the cause and effect relationship.

Conclusions

In summary, the present study along with others provides evidence that lower BMR was associated with both lower appendicular muscle mass and bone density in the lumbar spine and hip. Since the current study was a cross-sectional design, long-term prospective cohort studies are needed to monitor the occurrence of osteosarcopenia in postmenopausal women.

Abbreviations

ASMI: Appendicular muscle mass index; BIA: Bioelectrical impedance analysis; BMD: Bone mineral density; BMI: Body mass index; FFQ: Food frequency questionnaire; IPAQ: Physical activity questionnaire; MET: Metabolic equivalent of tasks; PTH: Intact parathyroid hormone.
**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12950-022-01754-6.

**Additional file 1:** Characteristics, biochemical and environmental factors based on osteoporosis classification.

**Acknowledgements**

The authors would like to thank the staffs of the bone density center of Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences.

**Author contributions**

ZMH performed conceptualization, project administration, investigation, formal analysis, methodology, writing—review and editing. MFH, SM, and PRA were major contributors in writing—review and editing. YD participated in sampling and data collection. AM and MR interpreted in data curation and validation. MFH was major contributor in editing Writing—review and editing. All authors read and approved the final manuscript.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

The data generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethical approval and consent to participate**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research ethics committee of Tehran University of Medical Sciences. The informed consent was obtained from all subjects. All methods were performed in accordance with the relevant guidelines and regulations and were approved by Tehran University of Medical Sciences.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**Author details**

1 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3 Osteoporosis Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 4 School of Nursing and Midwifery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 5 Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

**Received:** 5 January 2022  
**Accepted:** 6 April 2022  
**Published:** 14 May 2022

**References**

1. Cevei M, Onofrei RR, Coaraa F, Stoicanescu D. Correlations between the quality of life domains and clinical variables in sarcopenic osteoporotic postmenopausal women. J Clin Med. 2020;9(2):441.
2. Hirschfeld H, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int. 2017;28(10):2781–90.
3. Sjoblom S, Suuronen J, Rikkonen T, Honkanen R, Kroger H, Sirola J. Relationship between postmenopausal osteoporosis and the components of clinical sarcopenia. Maturitas. 2013;75(2):175–80.
4. Hamad B, Basaran S, Benhidjeg J. Osteosarcopenia among postmenopausal women and handgrip strength as a practical method for predicting the risk. Aging Clin Exp Res. 2020;32(10):1923–30.
5. Hassan EB, Duque G. Osteosarcopenia: a new geriatric syndrome. Aust Fam Phys. 2017;46(11):849–53.
6. Cileni N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. Biomed Res Int. 2014;2014:965764.
7. Yoo J, Ha Y-C. Review of epidemiology, diagnosis, and treatment of osteosarcopenia in Korea. J Bone Metab. 2018;25(1):1–7.
8. Paintin J, Cooper C, Dennison E. Osteosarcopenia. Br J Hosp Med Lond Engl. 2005;70(S):253–8.
9. Ko SH, Jung Y. Energy metabolism changes and dysregulated lipid metabolism in postmenopausal women. Nutrients. 2021;13(12):4565.
10. Polorsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med. 2010;28(3):426–34.
11. Gropper SS, Smith JL. Advanced nutrition and human metabolism. Boston: Cengage Learning; 2012.
12. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6(Suppl 2):S1–S209.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Endocrine S. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.
14. Mirmiran P, Esfahani FH, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr. 2010;13(5):654–62.
15. Committee IR. Guidelines for data processing and analysis of the international physical activity questionnaire (IPAQ)-short and long forms. 2005. http://www.ipaqsite/scoring.pdf.
16. Soysal P, Bulut EA, Yavuz I, Isik AT. Decreased basal metabolic rate can be an objective marker for sarcopenia and frailty in older males. J Am Med Dir Assoc. 2019;20(1):58–63.
17. Hsu WH, Hsu WR, Pan CT, Hsu RW. Predicting osteoporosis with body compositions in postmenopausal women: a non-invasive method. J Orthop Surg Res. 2021;16(1):215.
18. Abizanda P, Romero L, Sánchez-Jurado PM, Ruano TF, Ríos SS, Sánchez MF. Energetics of aging and frailty: the FRADeya Study. J Gerontol Ser A Biomed Sci Med Sci. 2016;71(6):787–96.
19. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2(10):819–29.
20. Elia M, Ritz P, Stubbs R. Total energy expenditure in the elderly. Eur J Clin Nutr. 2000;54(3):592–103.
21. Fukuzuka Y, Naita T, Fujita H, Moni T, Sato T, Sassa MH, Yamada Y. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig. 2019;10(2):322–30.
22. Beaudart C, Reginster J-Y, Petermans J, Gillian S, Quabron A, Locquet M, Sliomian J, Buckinx F, Bruyère O. Quality of life and physical components linked to sarcopenia: the SarcoPhAge study. Exp Gerontol. 2015;69:109–10.
23. Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. Geriatr Gerontol Int. 2014;14:15–28.
24. Han P, Zhao J, Guo Q, Wang J, Zhang W, Shen S, Wang X, Dong R, Ma Y, Kang L. Incidence, risk factors, and the protective effect of high body mass index against sarcopenia in suburban-dwelling elderly Chinese population. J Nutr Health Aging. 2016;20(10):1056–60.
25. Kim H, Suzuki T, Kim M, Kojima N, Yoshida Y, Hirano H, Sato K, Iwasa H, Shimada H, Hosioli E. Incidence and predictors of sarcopenia onset in community-dwelling elderly Japanese women: 4-year follow-up study. J Am Med Dir Assoc. 2015;16(1):e61–e68. e68.
26. Moreno-Aguilar M, Molina MM, Hernandez MPH. Inverse association between body mass index and osteosarcopenia in community dwelling elderly. Surg Obes Relat Dis. 2017;13(10):S190.
27. Shen Y, Chen J, Chen X, Hou L, Lin X, Yang M. Prevalence and associated factors of sarcopenia in nursing home residents: a systematic review and meta-analysis. J Am Med Dir Assoc. 2019;20(1):5–13.
28. Shapses SA, Sukumar D. Bone metabolism in obesity and weight loss. Annu Rev Nutr. 2012;32:267–309.
29. Hamrick MW, McGee-Lawrence ME, Frechette DM. Fatty infiltration of skeletal muscle: mechanisms and comparisons with bone marrow adiposity. Front Endocrinol. 2016;7:69.
30. Lee JH, Jun H-S. Role of myokines in regulating skeletal muscle mass and function. Front Physiol. 2019;10:42.
31. Harvey JA, Chastin SF, Skelton DA. How sedentary are older people? A systematic review of the amount of sedentary behavior. J Aging Phys Act. 2015;23(3):471–87.
32. Frost HM. A 2003 update of bone physiology and Wolff's Law for clinicians. Angle Orthod. 2004;74(1):3–15.
33. Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(9):e386–95.
34. Marty E, Liu Y, Samuel A, Or O, Lane J. A review of sarcopenia: enhancing awareness of an increasingly prevalent disease. Bone. 2017;105:276–86.
35. Kaji H. Interaction between muscle and bone. J Bone Metab. 2014;21(1):29–40.
36. Locquet M, Bruyère O, Lengoelé L, Reginster JY, Beaudart C. Relationship between smoking and the incidence of sarcopenia: the SarcoPhAge cohort. Public Health. 2021;193:101–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.